Evidence map›Paper›PMID 39991515›Full record

ArticleJournal of hepatocellular carcinoma2025

Machine Learning Prognostic Model for Post-Radical Resection Hepatocellular Carcinoma in Hepatitis B Patients.

Dalong Zhu, Alimu Tulahong, Abuduhaiwaier Abuduhelili, Chang Liu, Ayinuer Aierken, Yanze Lin, Tiemin Jiang, Renyong Lin, Yingmei Shao, Tuerganaili Aji

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dalong Zhu *Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Alimu Tulahong *Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Abuduhaiwaier Abuduhelili *Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Chang LiuDepartment of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Ayinuer AierkenDepartment of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Yanze LinDepartment of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Tiemin JiangDepartment of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Renyong LinState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Yingmei ShaoDepartment of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Tuerganaili AjiDepartment of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Primary liver cancer, predominantly hepatocellular carcinoma (HCC), constitutes a substantial global health challenge, characterized by a poor prognosis, particularly in regions with high prevalence of hepatitis B virus (HBV) infection, such as China. This study sought to develop and validate a machine learning-based prognostic model to predict survival outcomes in patients with HBV-related HCC following radical resection, with the potential to inform personalized treatment strategies. Patients and Methods: This study retrospectively analyzed clinical data from 146 patients at Xinjiang Medical University and 75 patients from The Cancer Genome Atlas (TCGA) database. A prognostic model was developed using a machine learning algorithm and evaluated for predictive performance using the concordance index (C-index), calibration curve, decision curve analysis (DCA), and receiver operating characteristic (ROC) curves. Results: Key predictors for constructing the best model included body mass index (BMI), albumin (ALB) levels, surgical resection method (SRM), and the American Joint Committee on Cancer (AJCC) stage. The model achieved a C-index of 0.736 in the training set and performed well in both training and validation datasets. It accurately predicted 1-, 3-, and 5-year survival rates, with Area Under the Curve (AUC) values of 0.843, 0.797, and 0.758, respectively. Calibration curve analysis and Decision Curve Analysis (DCA) further validated the model's predictive capability, suggesting its potential use in clinical decision-making. Conclusion: The study highlights the importance of BMI, ALB, SRM, and AJCC staging in predicting HBV-related HCC outcomes. The machine learning model aids clinicians in making better treatment decisions, potentially enhancing patient outcomes.

Indexed as

hepatitis B virushepatocellular carcinomamachine learningprognostic model

Identifiers

PMID39991515
PMCPMC11847427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.